TRX-221 is under clinical development by Therapex and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TRX-221’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TRX-221 overview
TRX-221 is under development for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. The drug candidate acts by targeting epidermal growth factor receptor (EGFR). It is administered through oral route.
Therapex overview
Therapex is a biopharmaceutical company primarily engaged in the discovery and development of new anti-cancer drugs to address unmet medical needs. The company’s main activities include precision medicine, targeted oncology, and innovative medicine, focusing on the development of personalized anti-cancer drugs based on molecular genotyping and drugs targeting oncogenic proteins and mutants. Therapex’s major products are in various stages of development, including TRX-221 for EGFR+ NSCLC, IBC-1131 for solid tumors, TRX-211 for EGFR+ NSCLC, TRX-212 for lymphoma, and undisclosed projects TRX-215 and TRX-214. It operates primarily in the biopharmaceutical industry, focusing on the development of anti-cancer drugs. The company’s target market is likely healthcare providers and patients in need of novel cancer treatments. Therapex is headquartered in Songpa-gu, Seoul, Republic of Korea.
For a complete picture of TRX-221’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
